In conclusion, our study suggested that the addition of cranial radiotherapy to osimertinib did not improve clinical outcomes compared to osimertinib alone in NSCLC patients with EGFR-positive mutations and brain metastases. This evidence concerns the gene EGFR and non-small cell lung carcinoma.